Allergan plc
Pharmaceutical & Health Products · Lobbying Client
Allergan plc's Federal Lobbying Record
Allergan plc's $8.6M in disclosed federal lobbying puts it in the mid-tier of registered filers. Spending in the seven-figure range is common for established trade groups, mid-size corporations, and advocacy organizations that maintain a steady but not aggressive presence on Capitol Hill.
Across the 5-year window from 2020 to 2024, Allergan plc's annual disclosed lobbying spend has climbed modestly — from $1.7M in 2020 to $1.8M in 2024, a change of +7%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.
Allergan plc's disclosed lobbying focuses on a narrow 4-issue footprint. A focused issue list usually means the organization concentrates its federal engagement on a small set of bills or rulemakings directly relevant to its core business.
1 of 6 lobbyists reported by Allergan plc (17%) disclose prior federal government service — a small minority of the named bench.
Among the named bench, lobbyists with disclosed prior federal service include Martha C. Choe (Former Senior Counsel, Senate Finance Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.
Within the Pharmaceutical & Health Products sector, Allergan plc ranks #21 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Allergan plc's $8.6M sits 48% below the sector average.
Allergan plc's LobbySpend Influence Score of 48/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.
Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.
Track Allergan plc's lobbying filings
Subscribe for LobbySpend updates by email. No spam, unsubscribe anytime.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2024 Oct-Dec | Jones Day | PHAHCRGOV | 4 | $372K |
| 2024 Jul-Sep | Cassidy & Associates | GOVPHAHCR | 1 | $365K |
| 2024 Apr-Jun | Venable LLP | PHAHCR | 2 | $413K |
| 2024 Jan-Mar | Peck Madigan Jones | PHAHCR | 2 | $523K |
| 2023 Oct-Dec | Capitol Counsel | GOVPHA | 3 | $343K |
| 2023 Jul-Sep | BGR Group | MEDGOV | 1 | $404K |
| 2023 Apr-Jun | Franklin Square Group | GOVHCRPHA | 4 | $473K |
| 2023 Jan-Mar | Summit Strategies Government Affairs | GOVHCRPHA+1 | 3 | $448K |
Allergan plc Lobbying FAQ
Allergan plc has spent $8.6M on federal lobbying across 4 policy areas. This includes spending on registered lobbyists and direct government contacts.
Allergan plc lobbies on 4 policy issues, including Health Issues, Pharmacy, Medical/Disease Research, Government Issues. These disclosures are filed quarterly with the Senate Office of Public Records.
Allergan plc has an Influence Score of 48/100 (Grade C). This proprietary score is based on total lobby spend (40%), policy issue breadth (30%), and revolving door connections (30%).
Allergan plc employs 6 registered lobbyists, of whom 1 have revolving door connections, meaning they previously held government positions before becoming lobbyists.
Allergan plc has contacted 7 government entities as part of their lobbying activities, including Dept of Homeland Security, Dept of Commerce, Federal Aviation Administration.
Explore Other Lobbying Organizations
$387.8M lobbying spend · Trade Association · Influence Score B
$348.2M lobbying spend · Real Estate · Influence Score B
$135.8M lobbying spend · Pharmaceutical & Health Products · Influence Score B
$128.0M lobbying spend · Healthcare · Influence Score B
Lobbying data is sourced from quarterly Lobbying Disclosure Act (LDA) filings with the Senate Office of Public Records. Influence Scores combine total spend (40%), issue breadth (30%), and revolving door connections (30%). Filings may be amended after initial submission.